ClinicalTrials.gg
RecruitingNCT05929508Updated Nov 17, 2025

Improving Mobility and Function Following Transfemoral Amputation: A Novel Approach to Reverse Volumetric Muscle Loss

An interventional study of Ischemic Preconditioning in Traumatic Amputation of Lower Extremity, sponsored by University of Illinois at Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Amputation, Traumatic with a site in United States — 12 open to participants now, 15 under way, 1 of them phase 3. Amputation, Traumatic · United States.

Planned enrollment
12th of 53
30 · median 12
Started
2024
with 2 others
No phase
47 of 64
8 open now
Primary completion
2027-06
later than 5 of 14 live
Registered
55th of 64
by date

Among the 64 studies in Amputation, Traumatic with a site in United States, this one is the 12th largest by planned enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2024, is one of 47 with no phase, reaches primary completion later than 5 of the 14 other live ones, and was the 55th registered.

Amputation, Traumatic

112 studies on the registry are indexed under Amputation, Traumatic; 24 are open to participants now.

Browse Amputation, Traumatic studies →

Open to participants now

12 of the 64 studies in Amputation, Traumatic with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Amputation, Traumatic studies recruiting now, 6 (33%) set no upper age limit and 9 (50%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Amputation, Traumatic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the relationship between thigh strength and walking ability and assess if using a blood pressure cuff on the leg improves strength and walking performance.

Read the detailed description

One in every 190 Americans is currently living with the loss of a limb. Following lower limb amputation (LLA), individuals have double the risk of knee and hip pain, a high prevalence of osteoarthritis in the intact limb with a prevalence ratio of 3.3 compared to those without amputation, and up to 90% experience severe back pain. The long-term consequences of LLA may be mitigated through regular use of prosthesis and physical activity, which would also increase the likelihood of returning to work and reintegration of Service Members (SMs) and younger Veterans.

Clinicians and researchers often focus on the prosthetic fit to improve outcomes, however just providing a prosthetic, even the most advanced prosthetic, is not enough to restore function. Interventions targeting physical capabilities to complement device intervention may be key to improving outcomes in individuals with LLA.

Along with increased orthopaedic risks, individuals with traumatic LLA also have an increased risk of cardiovascular events compared to the general population. SMs with traumatic unilateral transfemoral amputation have a 1.58 times greater risk of death from cardiovascular causes and their relative risk of aortic aneurysm is 5.1 times greater than Veterans without amputation. There is evidence to suggest that individuals with LLA have increased peripheral vascular resistance following amputation, leading to vasoconstriction and increased blood pressure. Reduced arterial function (i.e. increased arterial stiffness) is an important measure in those with LLA because it predicts mortality, heart failure, and cardiovascular events. In addition, improved arterial function improves perfusion to muscle and reduces fatigue during exertion. Therefore, strategies that reduce arterial stiffness and vascular resistance in individuals with LLA are important to improve mortality and quality of life for SMs and Veterans.

Therefore, we propose implementing ischemic preconditioning (IC) as a novel intervention to strengthen and hypertrophy leg muscles and increase arterial function for improving outcomes after amputation.

03

Conditions studied

  • Traumatic Amputation of Lower Extremity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years old
  • History of lower limb unilateral transfemoral amputation.
  • At least two years post lower limb amputation
  • Able to ambulate independently without the use of aids (i.e., walking cane).
  • Able to walk at least 10 minutes continuously without stopping.
  • Has a safe residuum with no open wounds on either the residual or intact limb.
  • Has a prosthetic limb with materials that are sound and safe to withstand the mobility requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Younger than 18 years old.
  • Inability to give .
  • Neurological disorder that affects gait.
  • Participants with significant metal (greater than one orthopaedic screw) in either the residual limb or the sound/intact limb
  • Participants who begin taking medications or change dosage of medications that could affect gait, balance, and cardiovascular function during the course of the study.
  • Currently pregnant (or intend to become pregnant while participating in study).
  • History of any condition where fatiguing contractions or resisted leg contractions are .
  • Blood clots in the leg, or any condition in which compression of the thigh or transient ischemia is contraindicated (e.g. open wounds in the leg).
  • History of uncontrolled hypertension.
  • History of heart failure.
  • Head injury within the previous 6 months.
  • Seizure disorder.
  • History of vascular disease.
  • History of thrombosis.
  • History of sickle cell trait.
  • History of genetic disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Ischemic Preconditioning at High Pressure

    In this arm, the participant will receive ischemic preconditioning (a blood pressure cuff on the intact limb) inflated to 225mmHg for 5 minutes followed by 5 minutes of reperfusion on a cycle for a total of 50 minutes. This will be completed every other day for 7 session (14 days).

    Other: Ischemic Preconditioning

  • Sham comparator
    Ischemic Preconditioning at Low Pressure

    In this arm, the participant will receive ischemic preconditioning (a blood pressure cuff on the intact limb) inflated to 25mmHg for 5 minutes followed by 5 minutes of reperfusion on a cycle for a total of 50 minutes. This will be completed every other day for 7 session (14 days).

    Other: Ischemic Preconditioning

Interventions

  • OtherIschemic Preconditioning

    A blood pressure cuff will be placed on the thigh of the intact/sound limb to restrict blood flow to the lower extremity for 5 minutes and then deflated for 5 minutes to allow for normal blood flow on a cycle for 50 minutes (5 times).

06

What researchers measure

Primary outcomes

  1. Strength

    Comparing leg strength before and after intervention

    Time frame: through study completion, an average of 6 weeks

  2. Gait

    Comparing leg strength before and after intervention

    Time frame: through study completion, an average of 6 weeks

  3. Metabolics

    Comparing leg strength before and after intervention

    Time frame: through study completion, an average of 6 weeks

  4. Daily Steps/Activity

    Comparing leg strength before and after intervention

    Time frame: through study completion, an average of 6 weeks

  5. Arterial Stiffness

    Comparing leg strength before and after intervention

    Time frame: through study completion, an average of 6 weeks

07

Study locations

1 of 1 sites recruiting
  • UIC Physical Therapy Faculty Practice
    Chicago, Illinois 60608, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Jun 2027, 38 months after the start.

Of 38 non-industry interventional studies with no phase under Amputation, Traumatic, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 58. This study's planned 38 months is above that.

Counting every sponsor, half of 46 studies reached it within 27 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2023
First posted
Jul 3, 2023
StartActual
Apr 1, 2024
Primary completionEst.
Jun 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05929508
Responsible party
Lindsay Hannigan (Assistant Professor, University of Illinois at Chicago) — Principal investigator
First posted
Jul 3, 2023
Start date
Apr 1, 2024
Primary completion
Jun 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 17, 2025

Study contacts

Lindsay Slater
Contact
slaterlv@uic.edu
3123558965
Lindsay Slater
principal investigator · University of Illinois at Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion